Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 159

Cited In for PubMed (Select 12970440)

1.

What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?

Alexander MR, Ringe R, Sanders RW, Voss JE, Moore JP, Klasse PJ.

J Virol. 2015 Jun 1;89(11):5981-95. doi: 10.1128/JVI.00320-15. Epub 2015 Mar 25.

PMID:
25810537
2.

Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells.

Mengistu M, Ray K, Lewis GK, DeVico AL.

PLoS Pathog. 2015 Mar 25;11(3):e1004772. doi: 10.1371/journal.ppat.1004772. eCollection 2015 Mar.

3.

Antibody engineering for increased potency, breadth and half-life.

Sievers SA, Scharf L, West AP Jr, Bjorkman PJ.

Curr Opin HIV AIDS. 2015 May;10(3):151-9. doi: 10.1097/COH.0000000000000148.

PMID:
25760931
4.

Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies.

Grimm SK, Battles MB, Ackerman ME.

PLoS One. 2015 Feb 17;10(2):e0117227. doi: 10.1371/journal.pone.0117227. eCollection 2015.

5.

Germlining of the HIV-1 broadly neutralizing antibody domain m36.

Chen W, Li W, Ying T, Wang Y, Feng Y, Dimitrov DS.

Antiviral Res. 2015 Apr;116:62-6. doi: 10.1016/j.antiviral.2015.02.001. Epub 2015 Feb 9.

PMID:
25676867
6.

Griffithsin tandemers: flexible and potent lectin inhibitors of the human immunodeficiency virus.

Moulaei T, Alexandre KB, Shenoy SR, Meyerson JR, Krumpe LR, Constantine B, Wilson J, Buckheit RW Jr, McMahon JB, Subramaniam S, Wlodawer A, O'Keefe BR.

Retrovirology. 2015 Jan 23;12:6. doi: 10.1186/s12977-014-0127-3.

7.

HIV-1 envelope glycoprotein trimer immunogenicity elicited in the presence of human CD4 alters the neutralization profile.

Forsell MN, McKee K, Feng Y, Mascola JR, Wyatt RT.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1089-98. doi: 10.1089/AID.2014.0104.

PMID:
25245278
8.

Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals.

Kardava L, Moir S, Shah N, Wang W, Wilson R, Buckner CM, Santich BH, Kim LJ, Spurlin EE, Nelson AK, Wheatley AK, Harvey CJ, McDermott AB, Wucherpfennig KW, Chun TW, Tsang JS, Li Y, Fauci AS.

J Clin Invest. 2014 Jul;124(7):3252-62. doi: 10.1172/JCI74351. Epub 2014 Jun 2.

9.

Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques.

Tong T, Crooks ET, Osawa K, Robinson JE, Barnes M, Apetrei C, Binley JM.

Virology. 2014 May;456-457:55-69.

10.

Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.

Sun M, Pace CS, Yao X, Yu F, Padte NN, Huang Y, Seaman MS, Li Q, Ho DD.

J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):473-83. doi: 10.1097/QAI.0000000000000218.

PMID:
24853313
11.

Single-vesicle architecture of synaptobrevin2 in astrocytes.

Singh P, Jorgačevski J, Kreft M, Grubišić V, Stout RF Jr, Potokar M, Parpura V, Zorec R.

Nat Commun. 2014 May 7;5:3780. doi: 10.1038/ncomms4780.

12.

Engineered Fc based antibody domains and fragments as novel scaffolds.

Ying T, Gong R, Ju TW, Prabakaran P, Dimitrov DS.

Biochim Biophys Acta. 2014 Nov;1844(11):1977-1982. doi: 10.1016/j.bbapap.2014.04.018. Epub 2014 May 2. Review.

PMID:
24792384
13.

Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).

Ringe R, Bhattacharya J.

Ther Adv Vaccines. 2013 Jul;1(2):67-80. doi: 10.1177/2051013613494534.

14.

CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies.

Madani N, Princiotto AM, Schön A, LaLonde J, Feng Y, Freire E, Park J, Courter JR, Jones DM, Robinson J, Liao HX, Moody MA, Permar S, Haynes B, Smith AB 3rd, Wyatt R, Sodroski J.

J Virol. 2014 Jun;88(12):6542-55. doi: 10.1128/JVI.00540-14. Epub 2014 Apr 2.

15.

Passive immunization against HIV/AIDS by antibody gene transfer.

Yang L, Wang P.

Viruses. 2014 Jan 27;6(2):428-47. doi: 10.3390/v6020428. Review.

16.

Antigenic properties of the HIV envelope on virions in solution.

Ray K, Mengistu M, Yu L, Lewis GK, Lakowicz JR, DeVico AL.

J Virol. 2014 Feb;88(3):1795-808. doi: 10.1128/JVI.03048-13. Epub 2013 Nov 27. Erratum in: J Virol. 2014 May;88(10):5901. Yu, Lei [added].

17.

Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein.

Kassa A, Dey AK, Sarkar P, Labranche C, Go EP, Clark DF, Sun Y, Nandi A, Hartog K, Desaire H, Montefiori D, Carfi A, Srivastava IK, Barnett SW.

PLoS One. 2013 Oct 16;8(10):e76139. doi: 10.1371/journal.pone.0076139. eCollection 2013.

18.

The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques.

McGee K, Haim H, Korioth-Schmitz B, Espy N, Javanbakht H, Letvin N, Sodroski J.

J Virol. 2014 Jan;88(1):21-40. doi: 10.1128/JVI.01558-13. Epub 2013 Oct 16.

19.

Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.

Ying T, Chen W, Feng Y, Wang Y, Gong R, Dimitrov DS.

J Biol Chem. 2013 Aug 30;288(35):25154-64. doi: 10.1074/jbc.M113.484154. Epub 2013 Jul 18.

20.

Development of prophylactic vaccines against HIV-1.

Schiffner T, Sattentau QJ, Dorrell L.

Retrovirology. 2013 Jul 17;10:72. doi: 10.1186/1742-4690-10-72. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk